Tag: inflammation

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –

London – 9 July 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling the initiation of a Phase I/II clinical trial in patients with primary IgA nephropathy (IgAN).

In this 2025 release, Ageless Shoulders expands its digital shoulder mobility system using traditional Indian club exercises to support joint flexibility, address frozen shoulder limitations, and meet rising search demand for non-surgical, at-home movement programs.

In this 2025 ingredient transparency update, Emma highlights growing public interest in methane-producing gut bacteria, microbiome imbalance, and non-clinical digestive support. The release explores how plant-based formulations may help support intestinal motility, microbial balance, and daily bowel regularity without relying on probiotics or synthetic cleanses.

Clean-label hydration meets real-world functionality in NativePath’s new stick pack assortment featuring natural flavors, third-party tested ingredients, and a complete hydration matrix designed for daily wellness.

WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today announced its entry into a warrant inducement agreement with a single institutional investor of the Company. Terms of the warrant inducement agreement include the immediate exercise of Series A-2 Warrants to purchase up to 957,200 shares of common stock (the “Series A-2 Warrants”) and Series A-3 Warrants to purchase up to 2,105,265 shares of common stock (the “Series A-3 Warrants,” and together with the Series A-2 Warrants, the “Existing Warrants”) at a reduced exercise price of $0.67. Gross cash proceeds were approximately $2.0 million before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

A new category of plant-based formulations is gaining attention for their role in supporting internal balance and inflammation-linked metabolic concerns. Among these is SlimJaro, which features botanical ingredients studied for their relation to digestion, inflammation, and cortisol support